4 completed, 1 not yet recruiting. 1 Not applicable, 1 Phase 1, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Transfusion-Dependent Thalassemia: new trials by email Literature Review of Transfusion-Dependent Thalassemia trials Research Report on Transfusion-Dependent Thalassemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Motivational Interviewing on Treatment Adherence and Self-Efficacy Among Omani Adults With Thalassemia Motivational Interviewing - Beta-Thalassemia Major, Transfusion-Dependent Thalassemia | Not applicable | Not yet recruiting | Oman Ministry of Health | 45 | 2026-11-01 | 2026-06-22 |
| Efficacy of Combination of Hdroxyurea and Thalidomide Over Hydroxyurea or Thalidomide in the Treatment of Transfusion Dependent Thalassemia in Children Thalidomide, Hydroxy Urea, Combinations - Transfusion-dependent Thalassemia | Phase 4 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 90 | 2023-11-01 | 2026-06-17 |
| Safety & Efficacy of Thalidomide in Children With Transfusion Dependent Thalassemia Thalidomide Capsules, Placebo - Transfusion-dependent Thalassemia | Phase 1 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 60 | 2023-03-01 | 2024-04-09 |
| Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet Deferasirox dispersable tablet (DT), Deferasirox film coated tablet (FCT) - Transfusion-dependent Thalassemia, Non-transfusion-dependent Thalassemia | Phase 2 | Completed | Novartis Pharmaceuticals | 148 | 2017-07-27 | 2021-10-04 |
| Endocrine Function During Deferasirox Therapy Iron Overload, Transfusion-dependent Thalassemia | Completed | University of Campania Luigi Vanvitelli | 426 | 2016-11-02 | 2020-08-17 |
Thalassemia (3) · Iron Overload (1) · Treatment Adherence and Compliance (1) · beta-Thalassemia (1)
Anemia (3) · Anemia, Hemolytic (3) · Anemia, Hemolytic, Congenital (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Hemoglobinopathies (3) · Behavior (1) · Health Behavior (1) · Iron Metabolism Disorders (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1)
Thalidomide (2) · Deferasirox (1) · Hydroxyurea (1) · Motivational Interviewing (1)
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (2) · Novartis Pharmaceuticals (1) · Oman Ministry of Health (1) · University of Campania Luigi Vanvitelli (1)
Bangladesh (2) · Egypt (1) · Italy (1) · Lebanon (1) · Morocco (1) · Saudi Arabia (1) · Thailand (1) · Turkey (Türkiye) (1) · Vietnam (1)
Mizna Said Al-sinani, RN,BSN (1)
PMID 17620452, PMID 18439858, PMID 29455932, PMID 34795208, PMID 35745672, PMID 36058507
2016 (1)